medigraphic.com

2015, Número 6

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2015; 53 (6)


Lupus eritematoso cutáneo, una entidad multidimensional

Méndez-Flores S, Tinoco-Fragoso F, Hernández-Molina G

Idioma: Español
Referencias bibliográficas: 33
Paginas: 764-772
Archivo PDF: 306.82 Kb.


RESUMEN

Las lesiones en la piel producidas por el lupus eritematoso sistémico constituyen una de las manifestaciones más frecuentes de esta enfermedad. Estas lesiones muestran una gran variabilidad, tanto en su expresión clínica como histológica, lo que dificulta su comprensión y estudio. Los pacientes que cursan con lupus cutáneo no necesariamente tienen complicaciones sistémicas graves, pero sí importante morbilidad por afección en la calidad de vida dada la extensión de las lesiones, tendencia a la cronicidad y el riesgo de cicatrices; de ahí la importancia de instaurar un tratamiento rápido y eficaz. El presente trabajo aborda las diferentes variedades de lesiones específicas atribuidas al lupus eritematoso, su correlación con actividad sistémica, calidad de vida y los tratamientos disponibles.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wysenbeek AJ, Block DA, Fries JF. Prevalence and expression of photosensitivity in systemic lupus erythematosus. Ann Rheum Dis. 1989; 48: 461-463.

  2. Léone J, Pennaforte JL, Delhinger V, Detour J, Lefondre K, Eschard JP, et al. Influence of seasons on risk of flare-up of systemic lupus: retrospective study of 66 patients. Rev Med Interne 1997; 18: 286-291.

  3. Werth VP. Cutaneous lupus: Insights into pathogenesis and disease classification. Bull NYU Hosp Jt Dis 2007;65:200-4.

  4. Sontheimer RD, Maddison PJ, Reichlin M, Jordon RE, Stastny P, Gilliam JN. Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 1982;97:664-71.

  5. Järvinen TM, Hellquist A, Koskenmies S, Einarsdottir E, Panelius J, Hasan T, et al. Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus. PLoS One 2010;5:e14212.

  6. Wenzel J, Zahn S, Tuting T. Pathogenesis of cutaneous lupus erythematosus: Common and different features in distinct subsets. Lupus 2010;19:1020-8.

  7. Paz ML, González Maglio DH, Pino M, Ferrari A, Weill FS, Nass- Wetter G, et al. Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity. Clin Rheumatol. 2011;30(2):209-16.

  8. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Ac Dermatol 1981; 4: 471-475.

  9. Kuhn A, Rondinone R, Doria A, Shoenfeld Y. 1st International Conference on Cutaneous Lupus Erythematosus Dusseldorf, Germany. Autoimmun Rev 2005;4:66-78.

  10. Obermoser G, Sontheimer RD, Zelger B. Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 2010;19:1050-70.

  11. Khun A, Ruzicka T. Classification of cutaneous lupus erythematosus. In Cutaneous Lupus Erythematosus. Springer-Verlag 2004; 11: 53-58.

  12. Lipsker D. Classification of specific cutaneous manifestations in patients with lupus erythematosus: A time for change? The concept of dermal lupus erythematosus. Dermatology 2006;212:324-6.

  13. Callen JP. Clinically relevant information about cutaneous lupus erythematosus. Arch Dermatol 2009; 145: 316-318.

  14. Vera-Recabarren MA, García-Carrasco M, Ramos- Casals M, Herrero C. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. Br J Dermatol 2010; 162: 91-101.

  15. Schmitt V, Meuth AM, Amler S, Kuehn E, Haust M, Messer G,et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 2010; 162: 64-73.

  16. Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P. Lupus erythematosus tumidus a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136: 1033-1041

  17. Kuhn A, Sonntag M, Ruzicka T, Lehmann P, Megahed M. Histopathologic findings in lupus erythematosus tumidus: review of 80 patients. J Am Acad Dermatol 2003;48:901-908.75.

  18. Vieira V, Del Pozo J, Yebra-Pimentel MT, Martínez W, Fonseca E. Lupus erythematosus tumidus: a series of 26 cases. Int J Dermatol 2006; 45: 512-517.

  19. Doutre M.S., Beylot C., Beylot J., et al. Chilblain lupus erythematosus: report of 15 cases. Dermatology. 1992;184: 26-28.

  20. Kolivras A, Aeby A, Crow Y.J. Cutaneous histopathological findings of Aicardi-Goutières syndrome, overlap with chilblain lupus. J Cutan Pathol 2008; 35(8): 774-8.

  21. Black DR, Hornung CA, Schneider PD, Callen JP. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol 2002; 138: 1175-1178.

  22. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-94.

  23. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997;133: 1433-40.

  24. Krathen MS, Dunham J, Gaines E, Junkins-Hopkins J, Kim E, Kolasinski SL, et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis Rheum 2008; 59: 338-44.

  25. Ayse Esra K, Murat S, lham S, Zeynep Nurhan S, Chren MM. Turkish version of Skindex-29. International Journal of Dermatology 2007;46: 350-355.

  26. Moghadam-Kia S, Chile K, Gaines E, Costner M, Rose M, Okawa J, Werth V. Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus– Associated Skin Lesions. Arch Dermatol. 2009; 145(3): 255-260.

  27. Méndez-Flores S, Orozco-Topete R, Bermúdez- Bermejo P, Hernández-Molina G. Pain and pruritus in cutaneous lupus: their association with dermatologic quality of life and disease activity. Clin Exp Rheumatol. 2013;31(6):940-2.

  28. Callen JP. Management of skin disease in patients with lupus erythematosus. Research Clinical Rheumatology 2002; 16: 245-264.

  29. Callen JP. Update on the management of cutaneous lupus erythematosus. Br J Dermatol 2004; 151: 731-736.

  30. Callen JP. Management of antimalarial-refractory cutaneous lupus erythematosus Lupus 1997; 6: 203-208. 81.

  31. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127: 513-518.

  32. Calvo-Alén Ja, Silva-Fernández L, Úcar-Anguloc E, Pego-Reigosad J, Olivée A, Martínez-Fernández C, et al. Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. Reumatología Clinica 2013; 9:281-296.

  33. Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheum 2012; 64: 2677-86.




2020     |     www.medigraphic.com